LimmaTech Biologics AG
LimmaTech Biologics AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at LimmaTech Biologics AG.
LimmaTech Biologics AG is a company.
Key people at LimmaTech Biologics AG.
Key people at LimmaTech Biologics AG.
LimmaTech Biologics AG is a Swiss clinical-stage biopharmaceutical company developing innovative vaccines against antimicrobial-resistant pathogens and sexually transmitted infections.[1][2][3] It advances a proprietary pipeline targeting threats like Staphylococcus aureus, Neisseria gonorrhoeae (gonorrhea), Chlamydia, Shigella (partnered with Valneva), and Candida (partnered with GSK), serving global populations facing rising antimicrobial resistance (AMR) and STIs by preventing severe, untreatable infections.[1][2][5] The company leverages self-adjuvanting, multi-antigen platforms to create cost-effective vaccines eliciting broad immune responses, with partnerships and funding like $2.2M from CARB-X signaling growth momentum in early clinical development.[3][5]
LimmaTech Biologics AG, based in Schlieren, Zurich, Switzerland, emerged from decades of expertise in microbial pathogen research, vaccine technologies, and clinical development.[2][3] While specific founders are not detailed in available sources, the company has built on pioneering advancements in next-generation vaccines, initially focusing on proprietary programs before expanding through strategic partnerships with GSK and Valneva.[1][2] A pivotal moment came in July 2023 with CARB-X funding for its gonorrhea vaccine, advancing it to hit-to-lead stage amid the global AMR crisis.[5]
LimmaTech rides the global AMR epidemic and rising STIs, where resistant pathogens like Neisseria gonorrhoeae threaten to overwhelm antibiotics, causing complications like infertility and HIV risk.[3][4][5] Timing aligns with urgent market forces: 82 million annual gonorrhea cases and few viable treatments, amplified by post-pandemic investment in biotech solutions.[5] It influences the ecosystem by pioneering preventive vaccines over reactive antibiotics, partnering with leaders like GSK and Valneva to scale impact, and securing non-dilutive funding like CARB-X to de-risk innovation in underserved infectious disease spaces.[1][2][5]
LimmaTech is poised to advance its gonorrhea vaccine through clinical stages, potentially delivering the first broad-spectrum preventive amid ceftriaxone resistance, while partnered programs with GSK and Valneva could yield milestones soon.[5] Trends like escalating AMR and STI surges will propel demand, with its platform enabling rapid adaptation to new threats. Influence may grow via more partnerships and approvals, transforming it from clinical player to global AMR leader—reinforcing its mission to protect against untreatable infections.[2][3]
